Lindbrook Capital LLC Sells 367 Shares of Illumina, Inc. (NASDAQ:ILMN)

Lindbrook Capital LLC lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 27.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 978 shares of the life sciences company’s stock after selling 367 shares during the period. Lindbrook Capital LLC’s holdings in Illumina were worth $136,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Illumina during the third quarter valued at about $29,558,000. abrdn plc grew its holdings in Illumina by 764.9% during the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company’s stock valued at $47,206,000 after purchasing an additional 299,827 shares during the period. International Assets Investment Management LLC grew its holdings in Illumina by 210.5% during the fourth quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company’s stock valued at $6,711,000 after purchasing an additional 32,672 shares during the period. Aquila Investment Management LLC grew its holdings in Illumina by 150.0% during the fourth quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company’s stock valued at $3,481,000 after purchasing an additional 15,000 shares during the period. Finally, Weil Company Inc. grew its holdings in Illumina by 59.2% during the third quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company’s stock valued at $3,152,000 after purchasing an additional 8,539 shares during the period. Institutional investors own 89.42% of the company’s stock.

Insider Transactions at Illumina

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The stock was purchased at an average cost of $135.29 per share, with a total value of $991,675.70. Following the purchase, the chief executive officer now owns 14,861 shares of the company’s stock, valued at $2,010,544.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.17% of the company’s stock.

Illumina Stock Up 3.5 %

Shares of ILMN stock opened at $124.46 on Wednesday. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $229.58. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. The stock’s 50 day simple moving average is $132.79 and its two-hundred day simple moving average is $127.58.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the business posted $0.14 earnings per share. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. Equities research analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have issued reports on ILMN shares. TD Cowen lowered Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target for the company. in a report on Thursday, January 4th. Stephens reaffirmed an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a research note on Wednesday, April 10th. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a research note on Tuesday, April 9th. Finally, HSBC lowered Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Illumina has a consensus rating of “Hold” and an average price target of $167.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.